Navigating mCRC: Treatment Options in the Third-Line Setting

Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

Dr Hochster on the Role of Cooperative Trials in Academic and Community Health Care Settings

Emerging role of doublet triplet therapies in R/R CLL: Expert Perspectives

Key Takeaways for Concurrent Biomarker Testing in NSCLC

Nuances With Defining “Refractory” mCRC in the Third-Line Setting

Dr Strickler on the Role of Biomarker Testing in Pancreatic Cancer

Dr Smaglo on the Evolution of RAS-Targeted Therapies for Pancreatic Cancer

Dr Pobel on the Prognostic Value of Phenotypic and Genomic Characterization in De Novo mCSPC

Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast Cancer

Overview of PERSEUS, IsKia, and GMMG-HD7

Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

Looking Ahead and Key Takeaways

Optimizing Regimens and Managing Adverse Events in TIE NDMM

Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

Dr Grunwald on Monitoring Risk Factors for Disease Progression in PV

Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease

Dr Allan on Efforts to Clarify the Optimal Treatment Sequence in CLL

Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL

Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management